BioMarin Pharmaceutical Inc.: Stifel cuts target price to $66 from $70
BMRN•Stifel cut its target price for BioMarin Pharmaceutical to $66 from $70.
Related News
Cabot forecasts fiscal 2027 adjusted EPS of $6.15-$6.75
CBT•
Spruce Power publishes update to financial calendar
SPRU•
Icahn Enterprises swings to Q3 2026 net loss of $225 million from year-earlier profit
IEP•
CACI wins five-year, $108 million U.S. Air Force contract to modernize financial operations
CACI•
CPKC sets all-time monthly grain shipment record in October
CP•